| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The primary target is MALT1 (paracaspase), a cysteine protease that mediates NF-κB activation downstream of B cell and T cell receptors. MALT1 cleavage activity is linked to the pathogenesis of activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL), a chemoresistant form of DLBCL. MI-2 contains a chloromethyl amide group that covalently and irreversibly binds to the catalytic cysteine of MALT1. This blocks MALT1-mediated cleavage of substrates including A20, BCL10, and RELB, and inhibits c-REL nuclear translocation, suppressing NF-κB signaling.
|
|---|---|
| ln Vitro |
In vitro, MI-2 inhibits MALT1 protease activity with an IC50 of 5.84 μM in cell-free assays. It irreversibly inactivates MALT1, with inhibition increasing over time and reaching near 100%. In ABC-DLBCL cell lines (HBL-1, TMD8, OCI-Ly10), MI-2 suppresses NF-κB reporter activity, inhibits c-REL nuclear localization, and downregulates NF-κB target genes. GI50 values are 0.2, 0.5, 0.4, and 0.4 μM in HBL-1, TMD8, and OCI-Ly10 cells, respectively. MI-2 also induces apoptosis and cell cycle arrest in AML cell lines (THP-1, MV4-11).
|
| ln Vivo |
In vivo, MI-2 profoundly suppresses the growth of TMD8 and HBL-1 ABC-DLBCL xenografts in NOD-SCID mice at 25 mg/kg/day via intraperitoneal injection for 14-24 days. It has no effect on MALT1-independent OCI-Ly1 tumors, demonstrating selectivity. MI-2 is nontoxic to mice and shows selective activity against ABC-DLBCL cell lines in vitro and xenotransplanted ABC-DLBCL tumors in vivo. It is also effective against primary human non-germinal center B cell-like DLBCLs ex vivo.
|
| Enzyme Assay |
For non-cellular MALT1 protease assays, recombinant MALT1 (constitutively dimeric form) is incubated with the fluorogenic substrate Ac-LRSR-AMC (25 μM) in assay buffer. Serial dilutions of MI-2 are added, and enzymatic activity is measured by fluorescence quantification of AMC release. For irreversible binding kinetics, MALT1 is preincubated with MI-2 for 5-80 minutes followed by substrate addition. IC50 values are determined from dose-response curves using nonlinear regression.
|
| Cell Assay |
For cell-based assays, ABC-DLBCL cell lines (HBL-1, TMD8) or AML cell lines (THP-1, MV4-11) are cultured and treated with MI-2 at concentrations ranging from 0.122 to 62.5 μM. Cell viability is measured by CCK-8 assay to determine IC50 and optimal exposure times (4-72 hours). Apoptosis is assessed by flow cytometry and Western blot for cleaved PARP and caspase-3. Cell cycle analysis is performed by flow cytometry. NF-κB signaling is assessed by Western blot for p65, c-Rel, and MCPIP1.
|
| Animal Protocol |
For in vivo experiments, NOD-SCID or NSG mice are engrafted subcutaneously with HBL-1, TMD8, or OCI-Ly1 cells. Once tumors reach approximately 120 mm3, mice are randomized to receive intraperitoneal injection of MI-2 (25 mg/kg/day) or vehicle (5% DMSO) for 14-24 days. Tumor growth is monitored by caliper measurement or luciferase imaging. At study termination, tumors are harvested for TUNEL assay, Ki-67 staining, and c-REL immunofluorescence to assess apoptosis, proliferation, and NF-κB signaling.
|
| Appearance |
Typically exists as solid at room temperature
|
|---|---|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.